Baltimore-PSA velocity measured 10 to 15 years prior to prostate cancer diagnosis is a significant predictor of cancer-specific survival 2 to 3 decades later, according to the results of a study published in the Journal of the National Cancer Institute (2006; 98:1521-7).
The treatment paradigm for vesicoureteral reflux has undergone a significant shift in recent years. Endoscopic surgery has provided an effective, minimally invasive option that is gradually eliminating the need for prolonged antibiotic use, monitoring with voiding cystourethrograms (VCUGs), and open surgery in children with most grades and forms of VUR.
New York-Several promising agents in early stages of development may find a role in the treatment of prostate cancer, and two ongoing cooperative group trials will provide more definitive evidence about how best to use docetaxel (Taxotere) in the treatment of hormone-refractory prostate cancer (HRPC). At the Mount Sinai School of Medicine Chemotherapy Foundation Symposium here, the developments were reviewed by Noah M. Hahn, MD, assistant professor of medicine at the Indiana University Cancer Center in Indianapolis.
Atlanta-Magnetic resonance imaging has exciting new applications in diagnosing and evaluating of pediatric urologic conditions, according to several studies presented here at the 2006 American Academy of Pediatrics Section on Urology annual meeting.
Rochester, MN-Men who take non-steroidal anti-inflammatory drugs (NSAIDs) daily have a decreased risk for developing BPH and associated lower urinary tract symptoms, according to analyses of data collected in a longitudinal population-based cohort study of aging men.
Atlanta-Endoscopic treatment should be a front-line therapy for the management of grade V vesicoureteral reflux, according to the authors of a retrospective study from the National Children's Hospital in Dublin, Ireland.
Herbal supplements and other complementary therapies are surrounded by clinical and ethical issues, some involving urologists.
Doris Stoll, PhD, executive director of the residency review committees for urology and three other surgical specialties at the Accreditation Council for Graduate Medical Education, has retired after 17 years of service to the Council. Separately, David C. Leach, MD, executive director of the ACGME, has announced that he will retire in September 2007.
Urologist Peter Albertsen, MD, has been named medical director of the UConn Medical Group, a 350-member multi-specialty physician practice, and James Thornton has been named director of the 224-bed John Dempsey Hospital, creating a new leadership team for the health center’s clinical enterprise.
Ebek, Inc., is conducting a voluntary nationwide recall of its supplement product sold under the name Liviro3. Lab analysis of Liviro3 samples conducted by the FDA found the product contains the phosphodiesterase type-5 inhibitor tadalafil, making Liviro3 an unapproved drug.
The Society of Urologic Nurses and Associates (SUNA) has formed the SUNA Foundation in a move to further its commitment to excellence in urologic clinical practice and research.
Ikonisys Inc. has received FDA approval to market the oncoFISH bladder diagnostic application in the United States. In conjunction with the company’s proprietary Ikoniscope robotic digital microscopy platform, oncoFISH bladder enables automated testing of cells found in urine specimens to aid in the detection of bladder cancer.
A course of the investigational drug silodosin, 8 mg once daily for 12 weeks, was superior to placebo for the relief of both obstructive and irritative symptoms in men with BPH, two phase III studies showed. Secondary endpoints included improvement in maximum urine flow.
Researchers working with breast cancer stem cells have found 186 genes that together can predict the risk of recurrence in breast cancer patients.
Early detection and treatment of prostate cancer apparently have lived up to their potential. The annual statistical report of the American Cancer Society reports that deaths in the United States from the four leading types of cancer-including prostate cancer-have decreased for the second consecutive year.
The Urology Center, located in New Haven, CT, has added a new associate, M. Grey Maher, MD, who returns after completing a fellowship in female urology, reconstructive surgery, and urodynamics at UCLA Medical Center.
The TwinCrest Group has signed a national agreement with International Physician Networks to provide in-office pathology laboratories to its urology, gastroenterology, and dermatology member physicians.
The recently discovered infectious virus XMRV was found in two patients with prostate cancer, according to a study published in the Proceedings of the National Academy of Sciences.
The cost burden of prostate cancer is high, but it varies by treatment type, even when controlling for disease, age, and stage, according to a study by Peter Carroll, MD, and colleagues at the University of California, San Francisco.
Three-fourths of men treated with a combination of radiation seed implants and external beam radiation therapy for prostate cancer are cured of their disease 15 years following their treatment, according to a study published in the International Journal of Radiation Oncology*Biology*Physics (2007; 67:57-64).
Obesity may increase the risk of death from prostate cancer, even though it does not increase the overall risk that a man will be diagnosed with the disease, suggests a study to be published in Cancer.
Two new drugs for advanced renal cell carcinoma effectively increase progression-free survival in patients with the disease, according to separate studies published last week in the New England Journal of Medicine (2007; 356:125-34; and 115-24).
Repeated doses of the targeted radiopharmaceutical samarium Sm-153 lexidronam injection (Quadramet) are a safe and effective treatment option in patients with painful bone metastases secondary to prostate cancer, according to a multicenter, phase IV study published recently in the online edition of Cancer.
AUA has announced that Heddy Hubbard, PhD, MPH, RN will be the association's new director of guidelines.
Definitive therapy appears to improve survival in men with early-stage prostate cancer, researchers from the University of Utah, Salt Lake City, reported.
Two new methods for evaluating prostate cancer risk following primary treatment have shown promise in separate studies.
Repeated doses of the targeted radiopharmaceutical samarium Sm-153 lexidronam injection (Quadramet) are a safe and effective treatment option in patients with painful bone metastases secondary to prostate cancer, according to a multicenter, phase IV study published recently in the online edition of Cancer.
Increased water intake may improve some aspects of bladder function in older men, but the effects are too small to be clinically relevant, according to a study by Dutch researchers.
Bevacizumab (Avastin) in combination with interferon alfa-2a (Roferon-A) therapy in patients with first-line metastatic renal cell carcinoma appears to significantly improve progression-free survival compared with interferon alfa-2a therapy alone, according to recent findings from an unpublished interim analysis of phase III data.
Men taking statins to lower their cholesterol are not at increased risk for developing prostate cancer, according to an ongoing multicenter, prospective cohort study published in the Journal of the National Cancer Institute (2006; 98:1819-25).